You are here

Human & Experimental Toxicology
Share

Human & Experimental Toxicology

2016 Impact Factor: 1.802
2016 Ranking: 66/92 in Toxicology
Source: 2016 Journal Citation Reports® (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE

Editor-in-Chief
Kai Savolainen Finnish Inst. of Occupational Health, Helsinki, Finland
Editor for the Americas
A Wallace Hayes Harvard University and University of South Florida, USA


eISSN: 14770903 | ISSN: 09603271 | Current volume: 36 | Current issue: 10 Frequency: Monthly

Human and Experimental Toxicology (HET), an international peer reviewed journal, is dedicated to publishing preclinical and clinical original research papers and in-depth reviews that comprehensively cover studies of functional, biochemical and structural disorders in toxicology. The principal aim of the HET is to publish timely high impact hypothesis driven scholarly work with an international scope.

The journal publishes on:

  • Structural, functional, biochemical, and molecular effects of toxic agents
  • Studies that address mechanisms/modes of toxicity
  • Safety evaluation of novel chemical, biotechnologically-derived products, and nanomaterials for human health assessment including statistical and mechanism-based approaches
  • Novel methods or approaches to research on animal and human tissues (medical and veterinary patients) investigating functional, biochemical and structural disorder
  • in vitro techniques, particularly those supporting alternative methods

Papers submitted will be judged on the basis of scientific originality and contribution to the field and quality and subject matter. Authors must clearly identify chemically the material tested and briefly explain what novel toxic effect (s) or toxic mechanism (s) of the chemical are being reported and what their significance is.

HET will not accept case reports and case studies. HET will not accept papers on herbal or other extracts unless sufficient chemical characterization of the material under investigation is supplied.

Human and Experimental Toxicology (HET), an international peer reviewed journal, is dedicated to publishing preclinical and clinical original research papers and in-depth reviews that comprehensively cover studies of functional, biochemical and structural disorders in toxicology. The principal aim of the HET is to publish timely high impact hypothesis driven scholarly work with an international scope.

The journal publishes on:

  • Structural, functional, biochemical, and molecular effects of toxic agents
  • Studies that address mechanisms/modes of toxicity
  • Safety evaluation of novel chemical, biotechnologically-derived products, and nanomaterials for human health assessment including statistical and mechanism-based approaches
  • Novel methods or approaches to research on animal and human tissues (medical and veterinary patients) investigating functional, biochemical and structural disorder
  • in vitro techniques, particularly those supporting alternative methods

Papers submitted will be judged on the basis of scientific originality and contribution to the field and quality and subject matter. Authors must clearly identify chemically the material tested and briefly explain what novel toxic effect (s) or toxic mechanism (s) of the chemical are being reported and what their significance is.

HET will not accept case reports and case studies. HET will not accept papers on herbal or other extracts unless sufficient chemical characterization of the material under investigation is supplied.

Studies must address at least one of the following:

  • Adverse effects induced by a chemically defined substance and/or the mechanism underlying the toxic phenomenon
  • New techniques for assessing potential toxicity, including molecular and systems biology
  • Toxicological examinations of specific chemicals, both those showing adverse effects and those demonstrating safety, that meet current standards of scientific acceptability

Only papers that have not been previously published, that fit in the above mentioned scope, and that have been reviewed by experts in the field prior to publication will be accepted. Cover letters must state that the paper is new and original and is not under consideration for publication elsewhere. Papers pending in other journals will not be considered. Co-authors should be individuals who have contributed substantially to the content of the papers. All authors must declare any potential conflict of interest and all financial support.

Please click here for more information on our author services. If you require further information or help, please visit our support pages: http://www.sagepub.com/journalgateway/authorGateway.htm

 

Editorial Board
Susan M. Barlow Independent Consultant, UK
Nursen Basaran Haceteppe University, Turkey
Barbara D. Beck Gradient Corporation, Cambridge, USA
Bas J. Blaauboer University of Utrecht, Netherlands
A R Boobis Imperial College London, UK
Edward J. Calabrese University of Massachusetts, USA
Daniel A. Casciano Director, NCTR, USA
J K Chipman University of Birmingham , UK
Emanuela Corsini University of Milan, Italy
Edmond E. Creppy Univ of Bordeaux II, France
F.A. De Wolff Leiden University, Netherlands
Michael L. Dourson Toxicology Excellence for Risk Assessment, USA
S.J.S. Flora National Institute of Pharmaceutical Education and Research, India
Sidney Green Howard University, USA
Helmut Greim Technical University of Munich, Germany
Mary Gulumian NIOH, South Africa
E.S. Harpur Newcastle University, UK
Kenneth Hartigan-Go Department of Health Manila, Philippines
Philip Harvey Consultant Toxicologist, UK
Ivo Iavicoli University of Naples Federico II, Italy
Salmann H. Inayat-Hussain Petroliam Nasional Berhad, Malaysia
Thomas A. Lewandowski Gradient, USA
Timothy C. Marrs Food Standards Agency, UK
Professor John O'Brien Danone Vitapole, France
B. Kevin Park University of Liverpool, UK
Camilla Pease SEAC, Unilever Colworth, UK
Chada S. Reddy University of Missouri-Columbia, USA
Ivonne M.C.M. Rietjens Wageningen University, Netherlands
Tetsuo Satoh Chiba University, Japan
B. Schilter Nestle Research Center, Switzerland
Roel Schins Heinrich-Heine-University Dusseldorf, Germany
Bryan K. Shipp Corporate EH&S, Pfizer Inc, USA
Aristidis Tsatsakis Director of Laboratory of Toxicology Medical School, University of Crete, Greece
G.B. Van De Voet Leiden University, Netherlands
Secretary
Leila Ahlstrom Finnish Institute of Occupational Health, Finland
  • Academic Search Premier
  • BIOSIS database
  • Biological Abstracts
  • Chemical Abstracts Service (CAS)
  • Chimica
  • Clarivate Analytics: BIOSIS Previews
  • Current Citations
  • Current Contents / Life Sciences
  • Current Contents/ Life Sciences
  • EMBASE/Excerpta Medica
  • Elsevier BIOBASE/Current Awareness in Biological Sciences
  • ISI Discovery Agent
  • Index Medicus
  • Index Medicus (Ceased 2004)
  • Index Veterinarius
  • MEDLINE
  • Medical Documentation Service
  • Neurosciences Abstracts
  • Nutrition Abstracts & Review Series A: Human & Experimental
  • Nutrition Abstracts and Reviews
  • Pollution Abstracts
  • SciVal
  • Science Citation Index
  • Science Citation Index Expanded
  • Scopus
  • Manuscript Submission Guidelines: Human and Experimental Toxicology

    This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/het to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Human and Experimental Toxicology will be reviewed.

    There are no fees payable to submit or publish in this journal.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    1. What do we publish?
      1.1 Aims & Scope
      1.2 Article types
      1.3 Writing your paper
    2. Editorial policies
      2.1 Peer review policy
      2.2 Authorship
      2.3 Acknowledgements
      2.4 Funding
      2.5 Declaration of conflicting interests
      2.6 Research ethics and patient consent
      2.7 Clinical trials
      2.8 Reporting guidelines
      2.9 Data
    3. Publishing policies
      3.1 Publication ethics
      3.2 Contributor's publishing agreement
      3.3 Open access and author archiving
    4. Preparing your manuscript
      4.1 Formatting
      4.2 Artwork, figures and other graphics
      4.3 Supplementary material
      4.4 Reference style
      4.5 English language editing services
    5. Submitting your manuscript
      5.1 ORCID
      5.2 Information required for completing your submission
      5.3 Permissions
    6. On acceptance and publication
      6.1 SAGE Production
      6.2 Online First publication
      6.3 Access to your published article
      6.4 Promoting your article
    7. Further information

    1. What do we publish?

    1.1 Aims & Scope

    Before submitting your manuscript to Human and Experimental Toxicology, please ensure you have read the Aims & Scope.

    1.2 Article Types

    The journal is keen to publish original research and review articles on experimental, clinical and epidemiological studies of functional, biochemical and structural disorders induced by exposure to chemicals or drugs, materials, or for example airborne particles. The journal also publishes papers dealing with exposure of human in e.g. occupational environments, and papers dealing with risk assessment of chemicals or materials.

    Please note that reports involving human participants or animals must adhere to the respective legal and ethical guidelines.

    HET will not accept papers on herbal extracts unless the chemical composition of the extract has been sufficiently characterized to allow others to reproduce the work reported.   The method section of the paper must clearly describe, in sufficient details, the experimental methods to allow others to  reproduce the work reported in the paper.  HET no longer accepts case studies/reports.

    Summary of manuscript structure:

    Manuscripts should be typed, double-spaced, on one side of the paper only, and should be structured into sections as follows:

    Title page; Summary (abstract) and keywords; Introduction; Methods; Results; Discussion; Acknowledgements (details of supporting grants, permission for reproduction of copyright materials, etc.); References. Each section should begin on a new sheet. Other subsection headings within these main sections may be used but should be limited.

    The main title should be explicit and specific (80 character limit) and an abbreviated (running) title (40-50 character limit) should be given.

    The summary (abstract) should form a synopsis of the work, at the same time underlining the contribution of the research to the understanding of toxicology; it should be no more than 200 words in length.

    Keywords (3-6) must be supplied otherwise the paper cannot be included in the annual index.

    Review articles

    The editors invite review articles on relevant and current topics in toxicology. Each review should contain a summary, an introduction to the topic, a careful review of the relevant and current literature, conclusions of the reviewed literature and recommendations, if applicable. Both invited and solicited review can be published.

    The journal will publish both mini-reviews (about 10 typewritten, double-spaced pages) and full-length, more thorough reviews (not to exceed 50 typewritten, double-spaced pages).

    The reviews, either mini-reviews or full-length reviews, should provide a timely view on the topic covered. Figures, figure legends, tables and references are included within the allotted pages. These reviews should follow the reference, figure, figure legend and table system used for original articles published in Human and Experimental Toxicology.

    1.3 Writing your paper

    The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.

    1.3.1 Make your article discoverable

    When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online

    Back to top

    2. Editorial policies

    2.1 Peer review policy

    Human and Experimental Toxicology adheres to a blinded peer review process in which the reviewer’s name is  withheld from the author unless the reviewer requests a preference for their identity to be revealed.

    The Editors’ decision in the acceptance of a given paper is final.

    As part of the submission process you will be asked to provide the names of peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below: 

      • The reviewer should have no prior knowledge of your submission
      • The reviewer should not have recently collaborated with any of the authors
      • Reviewer nominees from the same institution as any of the authors are not permitted

    Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript. Authors must include 2-3 potential reviewers with current email address or the manuscript will be returned to the authors until such are added.

    2.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

      1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
      2. Drafted the article or revised it critically for important intellectual content,
      3. Approved the version to be published,
      4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    2.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    2.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    2.4 Funding

    Human and Experimental Toxicology requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    2.5 Declaration of conflicting interests

    It is the policy of Human and Experimental Toxicology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.

    2.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.

    2.7 Clinical trials

    Human and Experimental Toxicology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

    2.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    2.9 Data

    SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.

    Human and Experimental Toxicology requests all authors submitting any primary data used in their research articles to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility.

    Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor(s) may consider limited embargoes on proprietary data. The editor(s) can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office.

    Back to top

    3. Publishing Policies

    3.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

    3.1.1 Plagiarism

    Human and Experimental Toxicology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    3.1.2 Prior publication

    If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    3.2 Contributor's publishing agreement

    Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway.

    3.3 Open access and author archiving

    Human and Experimental Toxicology offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.

    Back to top

    4. Preparing your manuscript for submission

    4.1 Formatting

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    4.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.

    Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the costs from SAGE after receipt of your accepted article.

    4.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.

    4.4 Reference style

    Human and Experimental Toxicology adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines to ensure your manuscript conforms to this reference style.

    If you use EndNote to manage references, you can download the SAGE Vancouver EndNote output file.

    4.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    5. Submitting your manuscript

    Human and Experimental Toxicology is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/het to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    5.1 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.

    We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.

    5.2 Information required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    5.3 Permissions

    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway

    Back to top

    6. On acceptance and publication

    6.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.

    6.2 Online First publication

    Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.

    6.3 Access to your published article

    SAGE provides authors with online access to their final article.

    6.4 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos

    Back to top

    7. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Human and Experimental Toxicology editorial office as follows:

    Editor-in-Chief, Kai Savolainen at kai.savolainen@ttl.fi

    Member Subscription, Combined (Print & E-access)


    Individual Subscription, Combined (Print & E-access)


    Institutional Subscription, E-access


    Institutional Subscription, Print Only


    Institutional Subscription, Combined (Print & E-access)


    Institutional Subscription & Backfile Lease, E-access Plus Backfile (All Online Content)


    Institutional Subscription & Backfile Lease, Combined Plus Backfile (Current Volume Print & All Online Content)


    Institutional Backfile Purchase, E-access (Content through 1998)


    Individual, Single Print Issue


    Institutional, Single Print Issue